Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EBITDA (2016 - 2025)

CorMedix has reported EBITDA over the past 16 years, most recently at -$84994.0 for Q4 2025.

  • Quarterly results put EBITDA at -$84994.0 for Q4 2025, down 4375.35% from a year ago — trailing twelve months through Dec 2025 was -$88000.0 (down 2833.33% YoY), and the annual figure for FY2025 was -$88000.0, down 2833.33%.
  • EBITDA reached -$84994.0 in Q4 2025 per CRMD's latest filing, down from $8205.0 in the prior quarter.
  • Across five years, EBITDA topped out at $8205.0 in Q3 2025 and bottomed at -$14.7 million in Q4 2023.
  • Median EBITDA over the past 5 years was -$7.0 million (2022), compared with a mean of -$5.2 million.
  • Peak annual rise in EBITDA hit 142.11% in 2025, while the deepest fall reached 4375.35% in 2025.
  • Over 5 years, EBITDA stood at -$7.8 million in 2021, then dropped by 4.78% to -$8.2 million in 2022, then tumbled by 80.43% to -$14.7 million in 2023, then soared by 100.01% to $1988.0 in 2024, then plummeted by 4375.35% to -$84994.0 in 2025.
  • Business Quant data shows EBITDA for CRMD at -$84994.0 in Q4 2025, $8205.0 in Q3 2025, and -$5121.0 in Q2 2025.